Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Shield Thera (STX) Share Price

Price 10.10p on 04-02-2026 at 18:50:09
Change 0.00p 0%
Buy 10.50p
Sell 9.70p
Last Trade: Buy 2,500.00 at 10.25p
Day's Volume: 3,218,146
Last Close: 10.25p
Open: 10.25p
ISIN: GB00BYV81293
Day's Range 10.25p - 10.25p
52wk Range: 2.20p - 12.35p
Market Capitalisation: £109.47m
VWAP: 9.882773p
Shares in Issue: 1.07b

Shield Thera (STX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 2,500 10.25p Suspected BUY Trade
16:35:25 - 04-Feb-26
Buy* 2,400 10.132p Ordinary
16:25:04 - 04-Feb-26
Buy* 477 10.479p Ordinary
15:10:27 - 04-Feb-26
Buy* 13 10.50p SI Trade
15:08:56 - 04-Feb-26
Sell* 40 9.70p SI Trade
15:08:56 - 04-Feb-26
Buy* 200,000 10.00p Ordinary
15:08:50 - 04-Feb-26
Buy* 100,025 9.9975p Ordinary
15:07:23 - 04-Feb-26
Buy* 100,000 9.95p Ordinary
14:52:23 - 04-Feb-26
Buy* 5,000 9.888p Ordinary
14:44:14 - 04-Feb-26
Buy* 20,000 10.00p Ordinary
14:31:44 - 04-Feb-26
See more Shield Thera trades

Shield Thera (STX) Share Price History

Time period:
to
Date Open High Low Close Volume
4th Feb 2026 (Wed) 10.25 10.25 10.25 10.25 3,218,146
3rd Feb 2026 (Tue) 10.875 10.875 10.20 10.25 2,224,470
2nd Feb 2026 (Mon) 10.55 10.875 10.55 10.875 1,638,229
30th Jan 2026 (Fri) 11.75 11.75 10.75 10.75 2,181,730
29th Jan 2026 (Thu) 10.35 11.00 11.00 11.00 3,828,674
28th Jan 2026 (Wed) 9.90 10.35 10.35 10.35 1,270,586
27th Jan 2026 (Tue) 10.10 10.10 9.50 9.90 1,891,908
26th Jan 2026 (Mon) 10.75 10.75 9.25 10.10 5,330,298
23rd Jan 2026 (Fri) 10.75 10.75 10.50 10.75 1,010,831
22nd Jan 2026 (Thu) 10.50 10.75 10.50 10.75 1,084,324
21st Jan 2026 (Wed) 12.20 12.20 10.70 10.70 4,814,504
20th Jan 2026 (Tue) 11.25 11.25 10.75 11.25 2,346,755
19th Jan 2026 (Mon) 12.15 11.50 11.20 11.25 2,294,458
16th Jan 2026 (Fri) 12.15 12.20 12.20 12.20 1,258,025
15th Jan 2026 (Thu) 11.75 12.20 11.75 12.15 1,357,703
14th Jan 2026 (Wed) 11.25 11.75 11.25 11.75 3,427,579
13th Jan 2026 (Tue) 10.75 11.25 10.75 11.25 1,696,583
12th Jan 2026 (Mon) 10.50 10.75 10.50 10.75 1,380,565
9th Jan 2026 (Fri) 10.00 10.50 10.00 10.50 1,821,641
8th Jan 2026 (Thu) 10.50 10.50 10.00 10.00 1,010,034
7th Jan 2026 (Wed) 10.75 10.50 10.50 10.50 1,713,937
6th Jan 2026 (Tue) 10.50 10.75 10.50 10.75 1,127,417
5th Jan 2026 (Mon) 9.85 10.50 10.50 10.50 2,942,753
See more Shield Thera price history

Shield Thera (STX) Regulatory News

Date Source Headline
30th Jan 2026 7:05 am RNS Total Voting Rights
30th Jan 2026 7:00 am RNS Approval for ACCRUFeR in China expected in Q1 2026
21st Jan 2026 7:00 am RNS Q4 2025 Trading Update
2nd Jan 2026 11:06 am RNS Block listing 6 Monthly Return
2nd Jan 2026 7:00 am RNS Total Voting Rights
2nd Jan 2026 7:00 am RNS Total Voting Rights
22nd Dec 2025 7:00 am RNS FDA approves extension for ACCRUFeR®
22nd Dec 2025 7:00 am RNS FDA approves extension for ACCRUFeR®
18th Dec 2025 7:13 am RNS Block Listing Application
11th Dec 2025 7:00 am RNS-R Shield Wins Gold at Titan Branding Awards
See more Shield Thera regulatory news

Shield Thera (STX) Share News

EARNINGS AND TRADING: Peel Hunt upbeat; Transense cuts profit outlook

30th Jan 2026 16:12

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

Shield Therapeutics reaches cash flow positivity as revenue grows

21st Jan 2026 16:24

(Alliance News) - Shield Therapeutics PLC on Wednesday said it achieved operating cash flow positivity in the fourth quarter of 2025, as it guided an operating profit in 2026. Read More

EARNINGS AND TRADING: Corel loss widens; Christie sells Vennersys

22nd Dec 2025 15:38

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

Shield Therapeutics upbeat as Accrufer trial initiated in Japan

14th Nov 2025 12:08

(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More

IN BRIEF: Shield receives approval from South Korea for Accrufer

7th Nov 2025 17:03

(Alliance News) - Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that the Korean Ministry of Food and Drug Safety has granted regulatory approval for Accrufer in South Korea for the treatment of iron deficiency in adult subjects. The approval follows submission of a new drug application by Korea Pharma in 2024 after the successful completion of a pharmacokinetic study. Shield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales. Read More

See more Shield Thera news
FTSE 100 Latest
Value10,402.34
Change87.75

Login to your account

Forgot Password?

Not Registered